ALLMedicine™ Invasive Lobular Carcinoma Center
Research & Reviews 290 results
https://emedicine.medscape.com/article/1954658-overview
May 10th, 2022 - Overview Breast cancers usually are epithelial tumors of ductal or lobular origin. Breast cancers are classified as follows: Ductal carcinoma in situ (DCIS) Lobular carcinoma in situ Invasive ductal carcinoma (ductal breast cancer) Invasive lobula...
https://emedicine.medscape.com/article/1954658-print
May 10th, 2022 - Breast cancers usually are epithelial tumors of ductal or lobular origin. Breast cancers are classified as follows: Ductal carcinoma in situ (DCIS) Lobular carcinoma in situ Invasive ductal carcinoma (ductal breast cancer) Invasive lobular carcino...
https://doi.org/10.5858/arpa.2021-0520-OA
Archives of Pathology & Laboratory Medicine; Ersoy E, Elsayad M et. al.
May 6th, 2022 - Touch preparation (TP) alone is discouraged for intraoperative lymph node (LN) assessment in the neoadjuvant setting (NAS) owing to overall low sensitivity in detecting metastatic breast cancer. To compare the sensitivity, specificity, and negativ...
https://doi.org/10.1038/s41379-022-01084-w
Modern Pathology : an Official Journal of the United Stat... Soong TR, Dillon DA et. al.
Apr 29th, 2022 - Invasive lobular carcinoma with extracellular mucin (ILCEM) is a rare histologic subtype of breast cancer. Little is known about the pathologic or genomic signatures that distinguish ILCEM from classic invasive lobular carcinoma (ILC) or mucinous ...
https://doi.org/10.1007/s10549-022-06572-w 10.1001/jama.289.11.1421 10.1007/s10549-012-2002-z 10.1177/1758834016644156 10.1016/j.critrevonc.2014.07.003 10.1200/JCO.2007.14.9336 10.1016/j.ejca.2003.08.007 10.1200/JCO.2015.64.0334 10.1016/j.ejca.2007.10.009 10.1186/bcr767 10.1158/1078-0432.CCR-20-2268 10.1200/jco.2012.30.15_suppl.612 10.1038/s41379-021-00742-9 10.1371/journal.pone.0235790 10.1007/s10552-018-1121-1 10.1053/j.semdp.2009.12.009 10.1016/j.anndiagpath.2009.03.004 10.1634/theoncologist.2018-0363 10.1007/s12282-013-0489-8 10.1016/j.cell.2015.09.033 10.1186/s13058-015-0519-x 10.1097/PAS.0b013e3182918a2b 10.1007/s10549-011-1860-0 10.1172/JCI41695 10.1097/01.pas.0000213386.63160.3f 10.1186/s13058-015-0605-0 10.1186/s13058-015-0606-z 10.1038/bjc.1984.135 10.1038/bjc.1991.145 10.1016/j.breast.2013.06.001 10.1002/jso.2930480106 10.2214/AJR.13.11156 10.1002/cam4.331 10.1002/onco.13734 10.1016/j.ccell.2018.08.008 10.1038/s41523-019-0104-z 10.1002/gcc.22716 10.1016/j.canlet.2019.06.011 10.1038/s41523-020-00195-4 10.1038/s41588-018-0287-5 10.1186/s13058-020-01324-4 10.1007/s10549-021-06383-5 10.1056/NEJMoa1813904 10.6004/jnccn.2015.0131 10.1038/s41698-017-0017-y 10.1038/s41523-019-0110-1 10.1038/s41565-019-0381-6 10.18632/oncoscience.414 10.1634/theoncologist.2020-0069 10.1038/bjc.2016.198 10.1158/1078-0432.CCR-13-0295 10.1186/s13058-020-01379-3 10.1016/j.ctrv.2021.102287 10.1126/scisignal.2004088 10.1158/1078-0432.CCR-18-4044 10.1186/s13058-015-0546-7 10.1158/1055-9965.EPI-11-0775 10.1007/s10689-016-9869-5 10.1158/1055-9965.EPI-18-1102 10.1007/s10549-012-1993-9 10.1200/JCO.21.00640 10.1016/S0002-9440(10)65129-2 10.1136/jmedgenet-2015-103094 10.2147/CLEP.S206949 10.1086/421251 10.1200/JCO.2014.57.1414 10.1007/s10549-017-4531-y 10.1038/bjc.1997.540 10.3389/fonc.2020.590643 10.1111/tbj.12455 10.1111/j.1524-4741.2009.00833.x 10.1016/j.breast.2004.03.004 10.1245/s10434-011-1907-9 10.1186/1477-7819-12-56 10.1186/s12885-016-2275-4 10.1371/journal.pone.0182397 10.1007/s10549-019-05234-8 10.1111/his.12572 10.1016/j.breast.2021.07.011 10.1111/tbj.12445 10.1111/tbj.12751 10.1002/cncr.25269 10.1245/s10434-018-6687-z 10.2217/bmm-2018-0396 10.1007/s10549-017-4355-9 10.1038/s41523-021-00368-9 10.1002/cncr.33104 10.4137/BMI.S38435 10.1016/S0959-8049(20)30542-6 10.1007/s10549-021-06429-8 10.1158/1078-0432.CCR-20-0260 10.1016/j.clbc.2020.01.013 10.1038/s41523-019-0113-y 10.1007/s40487-019-00105-0 10.1200/EDBK_100002 10.1007/s10549-011-1735-4 10.1245/s10434-019-07564-9 10.1200/JCO.2015.60.8133 10.1158/0008-5472.CAN-13-2779 10.1016/j.ejca.2017.11.014 10.1158/1535-7163.MCT-07-0312 10.1158/1078-0432.CCR-04-0438 10.1007/s00428-005-0003-6 10.1016/S1470-2045(19)30804-6 10.1111/tbj.13740 10.3390/jpm10040291 10.1056/NEJMoa1109653 10.1200/jco.2014.32.26_suppl.152 10.1093/jnci/djx268 10.1038/modpathol.2017.79 10.1038/srep18517 10.1158/0008-5472.CAN-11-4208 10.1038/s41598-018-25357-0 10.1007/s10549-017-4537-5 10.1158/1078-0432.CCR-17-3452 10.1016/j.annonc.2021.03.212 10.1053/ejso.2002.1404 10.1200/JCO.2005.03.111 10.1038/bjc.2012.557 10.1007/s10549-012-2233-z 10.1007/s10549-014-2861-6 10.1007/s10549-013-2751-3 10.1097/01.pas.0000152138.89395.fb 10.1245/s10434-015-4603-3 10.1093/annonc/mdl114 10.1007/s10549-006-9397-3 10.1016/j.ejca.2003.08.015 10.1200/JCO.2007.15.0235 10.1093/annonc/mds180 10.1002/cncr.30699 10.1634/theoncologist.2018-0182 10.1309/AJCP7URIW0QETTAT 10.1007/s10549-019-05277-x 10.1016/j.humpath.2021.07.010 10.1093/ajcp/aqz194 10.1016/j.clbc.2018.04.006 10.1200/JCO.2012.46.2440 10.1200/JCO.2021.39.15_suppl.535 10.1158/2159-8290.CD-17-0603
Breast Cancer Research and Treatment; Mouabbi JA, Hassan A et. al.
Mar 30th, 2022 - Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer after invasive ductal carcinoma (IDC), accounting for 10-15% of all breast cancer cases. Although most ILCs are of the luminal A intrinsic subtype, with...
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT04252859
Sep 22nd, 2021 - According to the National Comprehensive Cancer Network (NCCN) 2018 guidelines FDG-PET/CT may be performed as an alternative to a contrast-enhanced CT of the chest, abdomen and pelvis and Tc-99m MDP bone scan for evaluation of distant metastatic di...
https://clinicaltrials.gov/ct2/show/NCT04101656
Feb 13th, 2020 - Breast cancer is the most common tumor among women; although its treatment used to be very aggressive, nowadays is based on the minimum effective treatment. In non-metastatic patients, the therapeutical strategy is based on surgery, systemic thera...
News 15 results
https://www.onclive.com/view/distinct-strategies-needed-for-treating-lobular-breast-cancer
Oct 6th, 2021 - Jennifer Yuchen Shih, MD, MS Although patients with invasive lobular carcinoma (ILC) are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct ...
https://www.onclive.com/view/novel-radiotherapy-techniques-expand-options-for-breast-cancer-patients
Oct 6th, 2021 - Susan J. Hoover, MD, FACS Associate Member Center For Women’s Oncology Moffitt Cancer Center Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatmen...
https://www.onclive.com/view/dr-voorwerk-on-rationale-for-atezolizumab-carboplatin-in-metastatic-lobular-breast-cancer
May 12th, 2021 - Leonie Voorwerk, a PhD student at the Netherlands Cancer Institute, discusses the rationale for examining the combination of atezolizumab (Tecentriq) plus carboplatin in patients with metastatic lobular breast cancer. This combination was examine...
https://www.onclive.com/view/developing-treatment-for-invasive-lobular-carcinoma
Nov 13th, 2020 - Steffi Oesterreich, PhD, professor and vice chair of Precision and Translational Pharmacology, University of Pittsburgh, discusses developing treatment for patients with invasive lobular carcinoma (ILC). Patients with ILC are usually treated the ...
https://www.mdedge.com/hematology-oncology/article/230076/breast-cancer/gene-signature-found-similarly-prognostic-ilc-and
Susan London
Oct 15th, 2020 - The MammaPrint 70-gene signature has similar prognostic performance in women with early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) and may help guide chemotherapy decisions, according to an exploratory analysis of t.
